Published in Blood Weekly, December 10th, 2009
"We examined the side effect profile in 16 patients with imatinib-resistant CML who received 140 mg dasatinib daily in our center. Dasatinib produced substantial and sometimes severe or even life-threatening side effects...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.